HealthNews

EQT is the only bidder for OmniActive Health Technologies. EQT and a consortium led by Temasek Holdings and Novo Holdings were competing for a controlling interest in the company. ET reported that EQT’s offer had been superior. Dhiraj Poddar declined to make any comments. Mariwala didn’t respond to ETs question. Temasek Holdings and Novo Holdings declined to comment.

“Talks will be continued with EQT, though it is possible that TA Associates abandons these discussions and begins a new stake-sale process later this year”, said a source familiar with the matter, who requested not to name themselves. Mariwala holds a minority stake of OmniActive. CRISIL’s ratings agency said on 22 January that “near-term revenue from the US will be moderate due to deferred product launches amid increased uncertainty regarding trade policies”.

OmniActive Health products include Lutemax 2020 in the botanical and specialty segments, Csimax in the metabolic health and weight-management segments, and Gingever in the active wellness and natural energies segments. These products are reportedly market leaders in the respective segments. CRISIL’s 22 January note stated that the group has an advantage on the market because of its long-standing relationships with clients through codevelopment and cobranding. OmniActive Health Technologies is vertically integrated for its major products. This includes direct sourcing from farmers of marigolds and prika. Its business is vulnerable to fluctuations in raw material prices and seasonality. The company has several arms that include overseas subsidiaries OmniActive Health Technologies Inc., OmniActive Health Technologies (Canada), Limited and OmniActive Health Technologies GMBH, Switzerland, and Indian subsidiaries Omnikan Earth Sciences Private Limited Omni Wellness and Nutrition Limited PAEON Wellness and Nutrition Limited and OmniActive Improving Lives Foundation. The company had revenue of proximately Rs 886 crores in 2024-25. Data is not available for this period.

Published on May 9, 2026, at 11:12 am IST
Join our community of over 2M+ professionals in the industry. Subscribe to our Newsletter for the latest industry insights & analyses.

Your smartphone is your portal to ETHealthworld!

HealthNews

Cloudnine acquires Apollos maternity chains Cradle

Mumbai. Cloudnine Hospitals will acquire ollo Cradle & ollo Fertility – a network across India of maternity & infant care centres. ollo Health and Lifestyle Limited will own a 9.9% stake, making it India’s largest non-financial investor. The company will also have a director on the board of directors, AHHL said Wednesday. Cloudnine is set to buy ollo Cradle. According to ET, the deal will be valued at proximately Rs 1,500 crore. ET reported earlier in June that ollo Hospitals Enterprises Ltd. had pointed a financial advisor to scout out buyers for ollo Cradle. AHLL is the operator of ollo Cradle, a network of 12 maternity clinics in Hyderabad and Bengaluru. AHLL also runs a network of ollo Fertility centres, a group of 20 fertility centers across India. The combined entity, ollo Cradle ollo Fertility, and Cloudnine, will operate over 55 centres in key Indian markets. This entity will bring together the strengths from ollo Cradle ollo Fertility, and Cloudnine, under a single management structure. The platform will enhance access to specialised healthcare for women, maternity and fertility services in diverse regions and income levels, while taking advantage of one of India’s largest pool of senior clinicians, supported by global clinical standards, according to the company. “Together, AHLL Chairperson, Dr Sangita Reddy, said that ollo will continue to expand women’s healthcare services across preventive, tertiary, and specialised care segments. Cloudnine Hospitals, a Bengaluru-based brand that specializes in maternity care and paediatrics, was founded in 2006 by Dr. R. Kishore Kumar and his co-founders Rohit M.A. M. Ramachandra and Vidya Kumar. Cloudnine is operated by Kids Clinic India Ltd and currently has 40 centers (as at March 2025). Cloudnine’s share is held by private equity firms True North and TPG NewQuest together with Temasek. The promoters hold around 10% and the remainder is through ESOPs. Cloudnine filed a draft of a red herring prospectus in 2022 for an initial public offering to raise Rs 1,200 crore. However, the plan was delayed due to volatile markets. The mother and child care market in India, estimated to be worth around Rs30,000 crores, is expected to grow at an annual compound rate of 15% over the next couple of years.

Published May 21, 2026 11:02 AM IST
Join our community of over 2 million industry professionals. Subscribe to the Newsletter to receive latest insights and analysis directly to your inbox.

Your smartphone is your portal to ETHealthworld!

HealthNews

Quadria-arm to back patient monitoring platform LifeSigns

New Delhi: Quadria Group’s healthcare venture arm, HealthQuad has has announced to invest an disclosed sum in AI-driven patient monitoring platform LifeSigns.

The fresh cital will be deployed in expanding the Chennai-based startup’s international footprint across Southeast Asia and the GCC region and strengthening its AI-led technology stack through selective integrations.

Founded in 2019, LifeSigns is a US FDA-proved continuous patient monitoring platform, which integrates medical grade wearable and cloud dashboard with a predictive AI engine to provide safety alters by monitoring, heart rate, respiration, temperature, blood pressure, and oxygen saturation.

It flags early signs of deterioration to enable timely clinical intervention and is stated to be adopted by 50 facilities across tier 2 cities.

So far the platform has monitored over 325,000 patients and generated more than 87,000 alerts.

According to a company release the platform has helped to reduced code blue incidents by 90 per cent, and lowered ICU readmissions by nearly 78 per cent.

Quadria’s $350 million HealthQuad Fund, backs new-age healthcare business models with global relevance.

LifeSigns is building that layer to detect deterioration early and enable timely intervention which can significantly improve outcomes and reduce healthcare costs at scale. This is a globally relevant model and where the next wave of healthcare will be built, said Rahul Agarwal, Partner, HealthQuad.

Published On May 11, 2026 at 03:06 PM IST

HealthNews

Paras Health unveils Umeed ke Sitare initiative for cancer survivors

New Delhi: Gurugram-based multispeciality hospital chain Paras Health on Wednesday launched ‘Umeed Ke Sitare‘- a program dedicated to honouring the courage, resilience, and recovery journeys of cancer survivors.

“With cancer cases rising steadily across India, the healthcare ecosystem is increasingly recognising the importance of holistic and patient-centric oncology care. Reinforcing this proach, Paras Health organised ‘Umeed Ke Sitare’ in Gurugram, Haryana,” the hospital said in a statement.

The program brought together cancer survivors, caregivers, oncologists, and healthcare professionals to celebrate stories of hope and perseverance while highlighting the emotional and psychological aspects of cancer recovery.

India reports more than 1.4 million new cancer cases and nearly 900,000 cancer-related deaths annually, according to estimates.

Cancer treatment often leaves a long-lasting emotional and physical impact on patients and their families. Recognising these challenges, Paras Health designed ‘Umeed Ke Sitare’ to acknowledge the strength of survivors while encouraging conversations around emotional
wellbeing, rehabilitation, and survivorship care, it added.

India is witnessing a significant rise in the cancer burden, and with it comes an urgent responsibility for healthcare institutions to continuously advance the standards of oncology care. The future of cancer treatment lies in precision—precision in diagnosis, clinical decision-
making, and personalised treatment pathways that improve both survival and quality of life,” Dr. Dharminder Nagar, Mananging Director at Paras Health said.

Furthr, Narang said that the hoispital has built a strong multidisciplinary oncology ecosystem led by experienced oncologists, advanced technologies, and integrated expertise across surgical, medical, and radiation oncology.

Vineet Aggarwal Group COO Paras Health said that as the cancer burden continues to grow across India, healthcare systems must evolve beyond conventional treatment models and build patient-centric ecosystems that combine clinical excellence with compassionate continuity of care.

“Oncology care today is not only about treating disease, but also about helping patients and survivors navigate one of the most challenging phases of their lives with confidence and dignity. At Paras Health, we remain committed to strengthening our oncology services through advanced infrastructure, multidisciplinary collaboration, and precision-driven treatment proaches.”

The initiative reflects a broader transformation underway in India’s healthcare sector, where providers are increasingly adopting more empathetic and holistic proaches to treatment.

The government introduced policies, strategic interventions, and financial assistance schemes to enhance prevention, early detection, treatment, and patient care nationwide.

The Ministry of Health and Family Welfare has been allocated a total of Rs 99,858.56 crore, for priortising cancer care in FY 2025-26.

Published On May 21, 2026 at 12:58 PM IST

HealthNews

India plans national registry to track implantable medical devices and patients

India plans to tighten oversight of implantable medical devices by creating a national registry to track products and patients, a move aimed at curbing overuse, fixing accountability and ensuring only certified devices are used.

The proposal is being considered at the highest level and an announcement is expected soon, a senior government official told ET.

According to the official, registry data will help guide policy measures and improve procurement at the national level for government-run schemes with clear distinction between quality vis-a-vis low-cost devices. It will help check che and low-quality imports from neighbouring countries, the official added. India’s medical devices sector is projected to grow to $50 billion by 2030.

It is currently at $15 billion, as per industry estimates. More than a million high-risk implants are currently used in India annually, including cardiac stents, orthopaedic joints, pacemakers and spinal devices.

The plan is to mandate maintenance of data records for all cardiac and orthopaedic implants in the first phase at the manufacturer, supplier and hospital levels. This will be expanded in phases to cover all devices.

India implants lakhs of devices every year but can’t trace them. A National Implant Registry will help find patients in a recall, track real-world safety and build Indian evidence, said Rajiv Nath, forum coordinator of the Association of Indian Medical Devices Industry.

The association is of the view that the registry will enable rid identification of patients during global device recalls or adverse events, and ensure end-toend accountability from the manufacturer to the patient.

India’s medical implant sector faces issues such as regulatory gs, dependence on imports, high costs and lack of specialised oversight. Efforts are being made to regulate the sector, including through introduction of the National Medical Devices Policy in 2023.

While cardiac stents top the list of medical devices associated with adverse events, there have been instances of faulty implants in the knee and spinal devices.